COLLEGIUM PHARMACEUTICAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.42 USD | +1.62% |
|
+4.54% | +18.32% |
| 04-11 | Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes | MT |
| 02-26 | Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating | MT |
Chart calendar Collegium Pharmaceutical, Inc.
75f35c30b.yKrYx0y-ZYx-wzwcvUozesbbDU_Tl9w1NvrdaywmxX8._fie6n36DLwhplYk7gx5T4uSOw7q06Z3eM6EWkpEpAuZ-62yKvZQ6QSLUw~e9462d64181fc846912c71509deb16e4
Upcoming events on Collegium Pharmaceutical, Inc.
Past events on Collegium Pharmaceutical, Inc.
| 2024-04-10 15:45 | Needham Healthcare Conference - Fireside Chat |
| 2024-02-22 16:30 | Q4 2023 Earnings Call |
| 2024-02-22 16:09 | Q4 2023 Earnings Release |
| 2023-11-28 16:00 | Piper Sandler Healthcare Conference - Fireside Chat |
| 2023-11-14 04:30 | Jefferies London Healthcare Conference - Fireside Chat |
| 2023-11-07 16:30 | Q3 2023 Earnings Call |
| 2023-11-07 16:01 | Q3 2023 Earnings Release |
| 2023-09-06 18:30 | PAINWeek Conference - Association Between Per Capita Prescribing |
| 2023-09-06 18:30 | PAINWeek Conference - Misuse and Abuse Trends Across COVID-19 |
| 2023-09-06 18:30 | PAINWeek Conference - Use of Causal Framework |
| 2023-09-06 18:30 | PAINWeek Conference - Real-world Impact of Abuse-Deterrent |
| 2023-09-06 18:30 | PAINWeek Conference - Severity of Medical Outcomes of Exposures |
| 2023-09-06 18:30 | PAINWeek Conference - Misuse/Abuse of XTAMPZA |
| 2023-09-06 18:30 | PAINWeek Conference - Prescription Opioid Misuse/Abuse |
| 2023-09-06 18:30 | PAINWeek Conference - Safety and Tolerability of Buprenorphine |
| 2023-09-06 18:30 | PAINWeek Conference - Treatment Characteristics of Chronic Low Back Pain |
| 2023-09-06 18:30 | PAINWeek Conference - Healthcare Cost and Resource |
| 2023-08-03 16:30 | Q2 2023 Earnings Call |
| 2023-08-03 16:01 | Q2 2023 Earnings Release |
| 2023-06-08 12:30 | Jefferies Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 297 296 0.3% | 310 311 -0.33% | 277 331 -16.36% | 464 460 0.96% | 567 565 0.38% | 584 |
|
EBITDA Million USD | Released Forecast Spread | 7,53 4,78 57.64% | 140 150 -6.85% | 118 165 -28.16% | 266 256 3.87% | 367 366 0.34% | 386 |
|
EBIT Million USD | Released Forecast Spread | -23,7 -22,3 -6.56% | 56,2 58,0 -3.01% | 17,6 70,5 -74.98% | 33,3 42,2 -21.08% | 167 153 8.91% | 215 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -22,7 -22,7 0.08% | 27,6 32,9 -16.23% | -3,37 48,3 -106.99% | -28,8 -17,9 -61.49% | 75,7 61,4 23.27% | 167 |
|
Net income Million USD | Released Forecast Spread | -22,7 -23,2 2.09% | 26,8 30,1 -11.05% | 71,5 109 -34.3% | -25,0 -15,3 -63.32% | 48,2 43,2 11.6% | 116 |
|
EPS USD | Released Forecast Spread | -0,68 -0,71 4.67% | 0,76 0,90 -15.93% | 1,86 2,89 -35.58% | -0,74 -0,64 -15.18% | 1,29 1,10 17.27% | 2,95 |
| Announcement Date | 27/02/20 | 25/02/21 | 24/02/22 | 23/02/23 | 22/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 27,4 81,5 -66.44% | 83,8 78,7 6.46% | 124 121 1.92% | 127 124 2.13% | 130 125 3.52% | 145 138 4.65% | 136 138 -2.07% | 137 140 -2.03% | 150 148 1.49% | 148 | 142 | 144 | 150 | 152 |
|
EBITDA Million USD | Released Forecast Spread | -4,48 41,9 -110.68% | 43,5 41,0 6.18% | 71,2 64,9 9.61% | 74,9 68,6 9.1% | 76,4 69,1 10.59% | 87,6 88,9 -1.49% | 85,8 88,5 -3.02% | 89,4 86,7 3.08% | 104 99,6 4.62% | 94,9 | 92,8 | 95,6 | 103 | 97,4 |
|
EBIT Million USD | Released Forecast Spread | -34,1 18,7 -282.61% | -10,0 11,2 -189.59% | 11,1 19,0 -41.55% | 20,5 21,4 -4.38% | 11,8 20,6 -43.06% | 24,6 34,9 -29.48% | 35,6 30,6 16.49% | 45,0 41,1 9.41% | 61,7 48,0 28.43% | 54,4 | 49,8 | 52,2 | 58,4 | 53,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -38,9 12,8 -404.13% | -15,8 0,37 -4389.39% | -6,65 2,40 -377.19% | 1,43 0,89 60.54% | -7,79 3,21 -342.84% | -17,6 18,2 -196.52% | 17,8 12,2 46.21% | 28,8 23,5 22.34% | 46,7 32,4 44.1% | 40,8 | 37,4 | 41,0 | 48,3 | 42,5 |
|
Net income Million USD | Released Forecast Spread | -25,0 12,3 -303.16% | -13,1 0,24 -5568.2% | -5,19 1,98 -362.44% | 0,46 1,27 -64.14% | -7,20 2,49 -388.73% | -17,4 9,59 -281.68% | 13,0 11,4 14.15% | 20,6 20,6 -0.06% | 31,9 23,3 36.86% | 25,7 | 24,7 | 29,3 | 36,6 | 31,4 |
|
EPS USD | Released Forecast Spread | -0,73 0,35 -310.07% | -0,39 0,18 -313.7% | -0,15 0,06 -350% | 0,01 -0,14 107.41% | -0,22 -0,15 -51.72% | -0,51 0,31 -262.42% | 0,34 0,29 18.26% | 0,61 0,52 18.06% | 0,82 0,60 36.67% | 0,65 | 0,63 | 0,75 | 0,94 | 0,82 |
| Announcement Date | 24/02/22 | 10/05/22 | 04/08/22 | 03/11/22 | 23/02/23 | 04/05/23 | 03/08/23 | 07/11/23 | 22/02/24 | - | - | - | - | - |
More events
Past sector events for Collegium Pharmaceutical, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- COLL Stock
- Calendar Collegium Pharmaceutical, Inc.
